Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.50 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.50 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.50 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.50 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.50 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | GABRP | O00591 | 1/20 | 0.31 |
| ▸ | GABRD | O14764 | 1/20 | 0.31 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.31 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.31 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.31 |
| ▸ | GABRE | P78334 | 1/20 | 0.31 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.31 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.31 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL190753 | 0.98 | GABRA1 (0.48) | GABRA1TSHRGABRG2GABRB3GABRA5 | |
| SCHEMBL14167470 | 0.86 | LMNA (0.41) | GABRA1TSHRGABRG2GABRB3GABRA5 | |
| Hydrochloric Acid SCHEMBL21048882 | 0.85 | LMNA (0.40) | GABRA1TSHRGABRG2GABRB3GABRA5 | |
| SCHEMBL3862705 | 0.82 | — | — | |
| SCHEMBL2110093 | 0.77 | GAA (0.32) | — | |
| Hydrochloric Acid SCHEMBL30918306 | 0.77 | LMNA (0.42) | GABRA1TSHRGABRG2GABRB3GABRA5 | |
| SCHEMBL2763372 | 0.76 | LMNA (0.40) | GABRA1TSHRGABRG2GABRB3GABRA5 | |
| SCHEMBL26187365 | 0.76 | LMNA (0.45) | GABRA1TSHRGABRG2GABRB3GABRA5 | |
| SCHEMBL15247510 | 0.75 | ADH1C (0.36) | — | |
| SCHEMBL8100667 | 0.75 | ADH1C (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023199238-A1 | NOVEL COMPOUNDS TO TREAT CYTOKINE RELATED DISORDERS | ZYDUS LIFESCIENCES LIMITED (IN) | 2023-10-19 | — | — | WO | claimed |
| CN-109705033-B | N-heteroaryl sulfonamide derivative, preparation and application | 杭州壹瑞医药科技有限公司 | 2021-03-30 | — | — | CN | claimed |
| CN-102448958-A | Pyrimidinyl and 1,3, 5-triazinyl benzimidazole sulfonamides and their use in the treatment of cancer | PATHWAY THERAPEUTICS LTD | 2012-05-09 | — | — | CN | claimed |
| US-12454547-B2 | Steroidal compositions and methods of treating lipogenic cancers | Asteroid Therapeutics (US) | 2025-10-28 | — | — | US | disclosed |
| US-20240245673-A1 | Papain-like protease (PLpro) inhibitors | PFIZER INC. (US) | 2024-07-25 | — | — | US | disclosed |
| WO-2024121779-A1 | PAPAIN-LIKE PROTEASE (PLPRO) INHIBITORS | PFIZER INC. (US) | 2024-06-13 | — | — | WO | disclosed |
| CN-117642385-A | Pesticidally active cyclic amine compounds | 先正达农作物保护股份公司 | 2024-03-01 | — | — | CN | disclosed |
| US-20230399319-A1 | Acylsulfamide Compound and Pharmaceutical Use Therefor | JAPAN TOBACCO INC. (JP) | 2023-12-14 | — | — | US | disclosed |
| US-20230399319-A1 | Acylsulfamide Compound and Pharmaceutical Use Therefor | JAPAN TOBACCO INC. (JP) | 2023-12-14 | — | — | US | disclosed |
| US-20230399319-A1 | Acylsulfamide Compound and Pharmaceutical Use Therefor | JAPAN TOBACCO INC. (JP) | 2023-12-14 | — | — | US | disclosed |
| US-20230340011-A1 | STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS | Asteroid Therapeutics | 2023-10-26 | — | — | US | disclosed |
| US-20100234386-A1 | QUINOXALINE DERIVATIVES AS PI3 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2010-09-16 | — | — | US | disclosed |
| US-20100234386-A1 | QUINOXALINE DERIVATIVES AS PI3 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2010-09-16 | — | — | US | disclosed |
| US-7592342-B2 | Quinoxaline derivatives as PI3 kinase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2009-09-22 | — | — | US | disclosed |
| US-7592342-B2 | Quinoxaline derivatives as PI3 kinase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2009-09-22 | — | — | US | disclosed |
| US-7592342-B2 | Quinoxaline derivatives as PI3 kinase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2009-09-22 | — | — | US | disclosed |
| US-20080293706-A1 | QUINOXALINE DERIVATIVES AS PI3 KINASE INHIBITORS | GLAXOSMITHKLINE LLC | 2008-11-27 | — | — | US | disclosed |
| US-20080293706-A1 | QUINOXALINE DERIVATIVES AS PI3 KINASE INHIBITORS | GLAXOSMITHKLINE LLC | 2008-11-27 | — | — | US | disclosed |
| US-20080293706-A1 | QUINOXALINE DERIVATIVES AS PI3 KINASE INHIBITORS | GLAXOSMITHKLINE LLC | 2008-11-27 | — | — | US | disclosed |
| WO-2008141065-A1 | QUINOXALINE DERIVATIVES AS P13 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12454547-B2 | Steroidal compositions and methods of treating lipogenic cancers | SREBF1, SREBF2, NR1H3 | GABRA1 2720/4885TSHR 2363/4885GABRG2 2096/4885 |
| US-20240245673-A1 | Papain-like protease (PLpro) inhibitors | PREP, PEPD, ACE | GABRA1 2175/4885TSHR 3240/4885GABRG2 2785/4885 |
| US-20080293706-A1 | QUINOXALINE DERIVATIVES AS PI3 KINASE INHIBITORS | PIP5K1A, PIK3CB, PIK3CG | GABRA1 4042/4885TSHR 4423/4885GABRG2 4449/4885 |
| US-20230340011-A1 | STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS | SREBF1, SREBF2, NR1H3 | GABRA1 2720/4885TSHR 2363/4885GABRG2 2096/4885 |
| US-20230399319-A1 | Acylsulfamide Compound and Pharmaceutical Use Therefor | NLRP3, NLRP1, NOD1 | GABRA1 2080/4885TSHR 4443/4885GABRG2 3045/4885 |
| US-20100234386-A1 | QUINOXALINE DERIVATIVES AS PI3 KINASE INHIBITORS | PIP5K1A, PIK3CB, PIK3CG | GABRA1 4042/4885TSHR 4423/4885GABRG2 4449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.